Compare NetApp Inc. (NTAP) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Organon & Co. Common Stock — how do they compare? NetApp Inc. trades at $218.8 (market cap $46.95B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: NetApp Inc. is far larger — about 13× Organon & Co. Common Stock's market cap, and NetApp Inc. pays the higher dividend (0.87%). Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Organon & Co. Common Stock for 0 Days on average.
| NTAP | OGN | |
|---|---|---|
Market Cap | $46.95B | $3.62B |
Volume | 2,358,705 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $239.23 | $13.81 |
52-Week Low | $94.11 | $5.70 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $45.90B | $11.04B |
Dividend Yield | 0.87% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $222.2, down 7.12% over the past day, yet maintains a strong fundamental profile with robust profitability margins and consistent earnings beats. The stock exhibits a bullish technical signal, supported by moving averages, though oscillators indicate potential overbought conditions. Recent strategic announcements at INSIGHT 2026, including AI infrastructure partnerships and new product launches, highlight the company's focus on capitalizing on data and AI-driven demand.
The outlook for NTAP is positive, driven by solid earnings growth, strategic AI initiatives, and favorable analyst sentiment, but risks include high valuation multiples, competitive pressures in the storage sector, and macroeconomic sensitivity. The consensus price target of $219.30 suggests limited near-term upside from current levels, warranting caution amid recent volatility.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
